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Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim
of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently
appeared in the drug market.Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and
media resources (e.g., e-newsgroups, chat-rooms, and e-newsletters) in 10 languages were carried out. Results. 25C-NBOMe is sold
online as legal LSD or as research chemical with different designations such as “Boom,” “Pandora,” “Holland film,” or “N-bomb.”
It is a partial agonist of 5-HT2A receptors. It is usually ingested orally/sublingually and, less commonly, nasally, through injection,
vaginally, rectally, and smoked. Its effects include sublingual numbing, stimulation, “body high,” hallucinations, dissociation, and
anxiety. 25C-NBOMe presents high risk of overdoses; acute toxicity and fatalities have been reported. Conclusions. 25C-NBOMe
consumption represents an emerging phenomenon with potential harmful effects. Its use is increased by its online availability at
low costs. Health and other professionals should be informed about this new trend of substance use.
1. Introduction
In the last few years, the recreational use of novel psy-
choactive substances (NPS) has rapidly increased as well as
their availability in the drug market. This new phenomenon
represents not only an unprecedented challenge in the field of
drug addiction, but also a fast growing problem from social,
cultural, legal, and political perspectives [1–3].
Throughout 2013, a new group of toxic phenethylamine
derivatives called NBOMe have gained prominence [4, 5].
They are phenethylamine derivatives of the 2C class of
hallucinogens, initially mentioned in Alexander and Ann
Shulgin’s book PIHKAL, which was a contentious publication
that thoroughly described the properties of a large variety of
psychoactive substances [6, 7].
One of the most common substances within NBOMe
group is 25C-NBOMe [4]. As a result of its recreational
use, various episodes of acute intoxication and fatalities have
recently been reported [4, 8, 9]. In addition, while a danger
of 25C-NBOMe is its general use by those who planned
to ingest it, a second danger is the accidental ingestion of
the compound by individuals ingesting counterfeited LSD;
according to anecdotal and media reports and scientific
testing, in fact, LSD users may often unwittingly ingest the
more dangerous 25C-NBOMe instead of LSD [10].
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Scientific evidence on pharmacology and effects of 25C-
NBOMe are poor. Through a systematic analysis of medi-
cal-scientific literature and online resources (e.g., websites,
drug fora, and chat-rooms), the aim of the present paper
was to provide an initial comprehensive review of the phar-
macology, metabolism, toxicity, and psychoactive effects of
the 25C-NBOMe compound, namely, 2-(4-chloro-2,5-di-
methoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
2. Methods
A literature search on 25C-NBOMe was carried out in
PsycINFO, Scopus, and PubMed databases. Results were
integrated with a multilingual qualitative assessment of a
range of websites, drug fora, and other online resources (i.e.,
e-newsgroups, chat-rooms, mailing lists, e-newsletters, and
bulletin boards); between January 2013 and January 2014
exploratory qualitative searches of 153websites in English and
Italian took place using generic and specific keywords, such as
“legal highs,” “research chemicals,” “online pharmacy,” “25C-
NBOMe,” “NBOMe,” “hallucinogens,” “hallucinogenic sub-
stances,” and “online pharmacies” in Google search engine.
Of these, 43 were considered to be relevant for the study
and as such were monitored on a regular daily, weekly, or
monthly basis, depending on their relevance. The remaining
110 websites were considered not to bear any interest for the
present study and thus were no longer monitored.
Further specific searches in the database provided by the
Global Public Health Intelligence Network (GPHIN) also
took place. This is a secure Internet-based early warning
system that gathers preliminary reports of public health
significance by monitoring global media sources near “real
time,” 24 hours a day, 7 days a week basis. GPHIN is operated
by the Public Health Agency of Canada and monitors news
sources and websites across the globe in 9 languages (e.g.,
English, French, Farsi, Portuguese, Arabic, Russian, Spanish,
and Chinese simplified/traditional) [11]. While a series of
algorithms were used and adjusted to capture relevant infor-
mation, analysis of relevant data since 2003 was also carried
out manually by a multidisciplinary and multilingual team of
analysts.
Permission for the study was granted by the School of
Pharmacy Ethics Committee, University of Hertfordshire,
Hatfield, UK (November 2013; PHAEC/10-42).
3. Results
3.1. 25C-NBOMe: An Emerging Hallucinogenic Substance in
the Drug Market. 25C-NBOMe, also known as NBOMe-
2CC, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland
film, and Dime [12], has been first synthesized in 2009 and
first mentioned in the scientific literature in 2011 by Ettrup
et al. [13, 14]. To our knowledge, the first case of 25C-NBOMe
ingestion was recordedin 2010 [15]. The drug is believed to
be manufactured in China, but shipments from Europe and
Canada have also been reported [5].
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Figure 1: Chemical structure of 25C-NBOMe.
25C-NBOMe is a N-(2-methoxy)benzyl derivative of the
psychedelic phenethylamine 2C-C (4-chloro-2,5-dimetho-
xyphenethylamine) [16] (Figure 1). It is derived from 2C-
C by substitution on the amine nitrogen with a 2-
methoxybenzyl (BOMe) group. 2C-C belongs to a group
of modified phenethylamine structures called dimethoxy-
phenyl-ethanamines, also known as 2C substitutes [16]. The
terminology “2C” was created by Alexander Shulgin et al.
to describe the two carbons between the amino group and
the benzene ring in the chemical structure [6, 16]. The 2-
methoxybenzyl group attached at a nitrogen atom in 25C-
NBOMe acts as protecting group in order to preserve the
functionality of the amine group during a reaction [12, 16].
This structural change allows a 16-fold increase in potency as
compared to other NBOMe compounds [16].
3.2. Pharmacology. The pharmacological properties of
NBOMe series were first investigated by Heim and collabo-
rators [17]. 25C-NBOMe acts as a potent partial agonist
for the 5-HT2A receptor and has been studied in its 11C
radiolabelled form as a potential ligand for mapping the
distribution of 5-HT2A receptors in the brain using positron
emission tomography (PET) [13].
25C-NBOMe is characterized by nanomolar affinity
towards the 5-HT2A receptor and has an agonistic binding
affinity of 2.89±1.05 nM in vitro [13]; consistently, it has been
described by Braden et al. as “superpotent” agonist of the 5-
HT2A receptors [18] and it is pharmacologically active even
at very low submilligram doses [16].
3.3. Availability. 25C-NBOMe has entered the drug market
in 2010 in the forms of blotter papers and liquid and
less commonly as tabs [12, 16]. Since then its diffusion
has been facilitated by an increased online availability on
websites where it is sold as “a legal alternative of lysergic
acid diethylamide (LSD)” or as a research chemical “not
for human consumption,” as well as in combination with
other substances such as 25D-NBOMe or 2,5-dimethoxy-4-
iodoamphetamine (DOI) [12]. Its price ranges from about $7
to about $10 [19].
3.4. Route of Administration and Dosage. 25C-NBOMe can
be consumed through several routes of administration. The
most common route of administration is the oral or sub-
lingual ingestion (mixed with solvents such as alcohol) by
soaking the liquid on a blotter and keeping it on the buccal
mucosa for several minutes or swallowing it; Lawn et al.
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undertook a survey study through the Global Drugs Survey
reporting that 81.2% of users administered the drug orally
or sublingually [20]. Less commonly, 25C-NBOMe can be
takennasally (insufflation and absorption of liquid solutions),
through injection (intravenously and intramuscularly), vagi-
nally, and rectally, and it can be smoked as freebase [12, 20, 21].
Several independent reports suggest that doses of swal-
lowed 25C-NBOMe range between 50 and 1200 𝜇g and that
hallucinogenic effects can be achieved at a dose of 50–200𝜇g
[12, 15, 21]. When administered sublingually, the threshold
for the onset of hallucinogenic effects reportedly is about
100–250𝜇g, with mild effects after 250–450𝜇g, strong after
450–800 𝜇g, and very strong over 800 𝜇g [12]. The effects
of insufflated 25C-NBOMe have been described as light
after 50–200𝜇g, mild after 200–350𝜇g, strong after 350–
700𝜇g, and very strong after higher doses [12]. Finally, several
independent users report to smoke the substance dissolving
10mg of 25C-NBOMe freebase in 30mL 99.9% isopropanol
and then to dry 1mL “doses” (300 𝜇g) onto plant matter to be
smoked in cigarettes or pipes; in this latter case, the threshold
for the onset of intense hallucinogenic effects is about 50–
200𝜇g [22].
Example doses reported on the drug fora involving
more rare routes of administration include “830 𝜇g, injected,”
“400𝜇g, rectally,” and “500𝜇g, vaginally” [21, 23, 24].
3.5. Effects
(i) Sublingual Numbness. When taken sublingually, the first
effects are anecdotally described as unpleasant.These include
a metallic chemical taste along with a sense of numbness
of the tongue and mouth, which can last up to an hour
after the ingestion. Numbness of the tongue and mouth has
been reported to be a key difference between blotter papers
containing LSD and those containing NBOMe drugs [25].
(ii) Body High. The “body high” can be described as a
generally mild, all-encompassing, soft but euphoric tingling
sensation. This tingling sensation is also accompanied by
spontaneous rushes of euphoria which become longer and
more drawn out proportional to the dosage consumed [12,
25].
(iii) Stimulation. 25C-NBOMe can have stimulants effects.
According to subjective reports, it generates a “unique” sense
of stimulation, which has been described as “energetic” but
at the same time devoid of any physical movement, unless
intentional. For some users, the stimulation can be quite
uncontrollable, occasionally resulting in bodily shakes and
a grinding of the teeth comparable to that of MDMA and
traditional stimulants such as amphetamine [12, 25].
(iv) Psychedelic Effects. They can differ significantly. These
include introspection, euphoria, acceleration of thought,
conceptual thinking, time distortion, increased empathy, and
sociability. Other effects, which become more common as
dosages increase, include depersonalization, derealization,
anxiety, dissociation, panic, and fear [25]. In addition, 25C-
NBOMe is able to cause a wide range of hallucinatory states,
Table 1: Summary of 25C-NBOMe effects.
Sublingual
numbness
Metallic chemical taste
Sense of numbness of the tongue and mouth
Body high Body tingling sensationRushes of euphoria
Stimulation Physical energetic stimulationBodily shakes and a grinding of the teeth
Psychedelic
effects
Introspection, euphoria, acceleration of thought,
conceptual thinking, time distortion, increased
empathy, and sociability
including visual and auditory hallucinations [12, 25]. Visual
effects of the drug include increased visual acuity, enhanced
pattern recognition, enhanced colors, and distortions (e.g.,
visual drifting, texture repetition, and tracers) [12, 25]. A
summary of 25C-NBOMe effects is given in Table 1.
A user reported the effects of a 500 𝜇g 25C-NBOMe nasal
insufflation as follows:
The kitchen started to swirl around, everything
became very colourful, the intensity increased
exponentially. It became way way more intense
than I had expected very very quickly. Panic
started to take hold and no matter what I did I
could not shake it off. I tried to reassure myself
and tried to calm down but as my world started
to become more and more chaotic and as I started
to completely lose myself I found this impossible
to do. . . Then things started to get really really
nasty. The thoughts in which the loop seemed to
be wrecking peoples’ lives were interlaced with the
thoughts that somehow I was doing something so
terrible, so humiliating and disgusting that the
whole world thought I was a joke and that I did
not deserve to live. I was completely dissociated
and out of the room, I was on the ground outside
being pelted with rubbish by hundreds of people.
There were ambulances, police cars and my dad
all whirling round.This image remained for a long
time. However after a while it was as if people
understood and whilst some still hated me others
were rooting me on to make it through to the other
side of this trip. [12]
Onset and duration of the effects largely depend on the
doses and the routes of administration (more details are
given in Table 2) [12, 15, 21]. Overall, the insufflation of 25C-
NBOMe seems to lead to more rapid, severe, and toxic con-
sequences than the oral/sublingual ingestion. Residual long-
lasting symptoms have been reported even several months
after 25C-NBOMe consumption [26].
3.6. Toxicity. Common negative physical side effects of
25C-NBOMe include vasoconstriction, nausea, vomiting,
headache, irregular heartbeat, sweating, and temporary dys-
uria [4, 25, 27]; some users anecdotally reported to have expe-
rienced “something terrifying to the body” after its consump-
tion [26].Overdoses lead tomost severe effects; some recently
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Table 2: Onset and duration of 25C-NBOMe effects in relation to
the routes of administration.
Oral/sublingual Insufflation
Total duration 4–10 hours 3–8 hours
Onset 0–15 minutes 0–5 minutes
Coming up 30–90 minutes 15–30 minutes
Coming down 1–4 hours 1–3 hours
reported cases of intoxicationwere associatedwith confusion,
agitation, hypertension, tachycardia, hyperthermia, dilated
pupils, heart failure, metabolic acidosis, generalized seizure,
loss of consciousness, low oxygen saturation, acute kidney,
and lung failures [25, 27–29].
As 25C-NBOMe is a potent serotonergic agonist, these
toxic effects may represent the clinical manifestations of
serotonin toxidrome, which is known to potentially produce
acute toxicity involving metabolic acidosis, rhabdomyolysis,
seizures, renal failure, and disseminated intravascular coagu-
lation.
25C-NBOMe is strongly active at extremely small doses
(it exerts its effects even at microgramic levels) and users may
not have precise weighing scale; therefore, the possibility of
accidental overdoses is not irrelevant. In addition, the lack
of knowledge of an experimentally recognized median lethal
dosage (LD50), the frequent poor or mistaken dilution, and
the improper handlings especially by teenagers (including the
concomitant use with other drugs like methoxetamine, 𝛼-
methyltryptamine, or synthetic cannabinoids) contribute to
increase the risk of accidental overdoses of the substance and
related deaths [28, 29].
Since June 2012,more than 10 fatalities have been reported
as a result of the ingestion of substances in the NBOMe class
[4, 27, 30–32] and at least 2 of these were attributable to 25C-
NBOMe; in 2013, a 16-year-old and an 18-year-old males died
in USA and UK after having inhaled the drug [9, 21, 25].
3.7. Legal Status. From a legislative point of view, NPSs are
often identified as temporary class drugs (TCDs); the TCD
is a relatively new status for controlled drugs which has
been adopted in some jurisdictions, notably New Zealand,
USA, and the United Kingdom, to attempt to bring newly
synthesized designer drugs under legal control [33].
In the United States the Controlled Substance Act (CSA)
is the federal drug policy under which the manufacture,
importation, possession, use, and distribution of certain
substances are regulated. CSA created five schedules (clas-
sifications), with varying qualifications for a substance to be
included in each; two federal agencies, theDrug Enforcement
Administration (DEA) and the Food and Drug Adminis-
tration (FDA), determine which substances are added to or
removed from the various schedules. Classification decisions
are required to be made on criteria including potential for
abuse, currently accepted medical use in treatment in the
United States, and international treaties. On November 2013
the DEA added 25I-, 25B-, and 25C-NBOMe to Schedule I
making these NBOMe compounds “temporarily” controlled
for two years. Sale, possession, manufacture, and distribution
of these three compounds are crimes under theUS federal law
[21, 34].
For what concerns the United Kingdom, a total of 10
benzofuran and indole analogues and four NBOMe hallu-
cinogens (25C-, 25B-, 25I-, and 25D-NBOMe) have been
classified as TCDs from June 2013 to be reviewed in June 2014.
This means that sale and import of the named substances are
considered criminal offences and are treated as Class B drugs
[21, 35, 36].
In New Zealand, 25C-NBOMe is considered to be
substantially similar in chemical structure to the illegal
hallucinogen dimethoxybromoamphetamine (DOB), being
therefore considered a Class C controlled drug analogue [21].
In addition, 25C-NBOMe is currently controlled under
drug control legislation in Denmark, Hungary, Israel, Lithua-
nia, New Zealand, Portugal, Romania, Russia (the first coun-
try that officially banned the compounds of NBOME series in
2011), Slovenia, Sweden, and areas of Australia (Queensland
and New South Wales) [21].
4. Discussion
Differently from the prevalence rates of the use of inter-
nationally controlled drugs which seem generally to have
stabilized in recent years, the market of NPS, also known as
“designer drugs,” “herbal highs,” “synthetic drugs,” “research
chemicals,” and “legal highs,” has significantly grown over
the past decade [37–40]. An ever-increasing number of NPS
are emerging worldwide, as witnessed through the EU Early
Warning System of the European Monitoring Centre for
Drugs andDrugAddiction (EMCDDA): 73 newpsychoactive
substances were officially notified for the first time in 2012,
up from 49 in 2011, 41 in 2010, and 24 in 2009 [41]. This can
be attributed to developments in manufacture, distribution,
administration, and communication of new recreational sub-
stances [3, 42–44].Therefore, it is crucial for both consumers
of recreational drugs and health professionals to be aware of
the effects and toxicity of NPSs so that proper toxicological
investigations and eventual medical interventions can be
performed.
Scientific literature on pharmacology and effects of 25C-
NBOMe is limited. Through a systematic analysis of the
current literature and other online resources (e.g., websites,
drug fora, and chat-rooms), the present paper aimed to pro-
vide fresh insights into the properties, effects, and potential
toxicity of this emerging psychoactive drug.
The lack of awareness on its potential risks and unclear
legal status of phenethylamine-class drug in various countries
may favor the diffusion of 25C-NBOMe among drug users.
According to anecdotal and media reports and scientific
testing [10], it is likely that LSD users may unwittingly ingest
the more dangerous and possibly lethal 25C-NBOMe instead
of LSD. On March 2013, the case of a woman who died after
having assumed two blotters of what she wrongly believed
to be LSD but that actually contained one of the NBOMe
compounds was reported in the media [45]. As a result,
emergencymedical personnel should be alerted and prepared
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to treat patients also for the accidental ingestion of a drug
in the NBOMe group, which necessitates more intensive care
than would otherwise be assumed [4, 46].
The patients may require benzodiazepines and other
drugs for the control of overdose-related psychiatric symp-
toms such as agitation, aggression, or hallucinations [28].
At the same time, all the potential organic sequelae such as
hypertension, hyperthermia, heart failure, metabolic acido-
sis, generalized seizure, acute kidney and lung failures, and
manifestations of serotonin toxidrome should be carefully
monitored. Appropriate treatments might include fluids,
aggressive cooling, pharmacological interventions, and other
high-level resuscitative measures [4]. For example, Grautoff
and Ka¨hler required mechanical ventilation and hemofiltra-
tion to treat a 19-year-old man who had inhaled 2mg of 25C-
NBOMe; the patient recovered after 13 days in the intensive
care unit [29].
A similar challenge emerged in the last few years with
the diffusion of the highly toxic and long lasting (up to 3
days) hallucinogenic drug Bromo-Dragonfly, which caused
a number of fatalities among LSD users before it was
recognized [47]. Both 25C-NBOMe and Bromo-Dragonfly
have not been approved for human consumption and can be
associated with unknown side effects/adverse reactions and
long term consequences [47].
From a psychiatric point of view, there is a lack of data
about long-lasting mental effects of 25C-NBOMe; however,
residual symptoms have been reported even several months
after its consumption [26]. Research suggests that the use of
psychedelic drugs in unsupervised, unscreened, and unorga-
nized settings (e.g., what is common for recreational drug
use) may result in adverse reactions such as anxiety, depres-
sion, or psychosis [48]. Given that the NBOMe compounds
have never been tested in humans, their use could result in
severe adverse psychiatric consequences.
The 25C-NBOMe incompletely characterized profile and
the lack of routine toxicological screening tests in many labo-
ratories make the substance hardly identifiable. Large studies
are needed to systematically investigate effects, toxicity, and
potential fatal role of 25C-NBOMe. Meanwhile, the attention
and clinical suspicion of families and healthcare professionals
towards this new substance is warranted.
One could wonder about the limitations of carrying out
an assessment of substance use whilst taking into account
online and media reports; in fact, it may be inappropriate to
trust information obtained from the Internet without inde-
pendent verification. However, the Internet plays a central
role in the NPS business and therefore, given the limited
amount of relevant peer-reviewed data, this seems to be the
only method to obtain preliminary information about new
and emergent phenomena [49, 50].
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